BC Innovations | Mar 24, 2016
Product R&D


Ionis Pharmaceuticals Inc. is retooling its antisense technology with a sugar-based conjugate that boosts uptake into liver cells. By tapping the power of GalNAc sugars to latch onto hepatocyte receptors, the company believes it can...
BC Innovations | Mar 24, 2016
Distillery Techniques

Techniques: Enhancing hepatocyte uptake of antisense oligonucleotides (ASOs) via conjugation to N-acetylgalactosamine (GalNAc) clusters targeting asialoglycopro

Drug delivery TECHNOLOGY: Other Conjugating ASOs to GalNAc clusters targeting ASGR1 could help improve hepatocyte uptake of antisense therapeutics. The GalNAc cluster consisted of a tris(hydroxymethyl)aminomethane scaffold containing a linker that could be conjugated to...
BC Innovations | Oct 31, 2013
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Coronary artery disease (CAD); myocardial infarction (MI) Apolipoprotein D (APOD) Mouse studies suggest APOD could help treat CAD and MI. In a mouse model...
BC Week In Review | Oct 22, 2012
Company News

Iverson Genetic, Johns Hopkins University School of Medicine deal

The university granted Iverson exclusive, worldwide commercialization rights for molecular diagnostics designed to help physicians assess cardiovascular risk in men and women and infertility risk in women. The diagnostics are based on the HDL partner...
BC Innovations | Jun 16, 2011
Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Immunocompetent, humanized mouse model for HCV infection An immunocompetent, humanized mouse model of HCV could help evaluate potential HCV entry inhibitors...
BC Innovations | Jun 16, 2011
Cover Story

HCV's mighty mouse

The most widely used animal model of HCV infection requires transplanting human hepatocytes into immunodeficient mice. These mice are useful for testing antivirals, but the absence of an immune system makes the animals unsuitable for...
BC Innovations | May 12, 2011
Cover Story

Making the most of the host

Although recent attention in the HCV space has focused on positive FDA panel recommendations for the protease inhibitors telaprevir and Victrelis boceprevir from Vertex Pharmaceuticals Inc. and Merck & Co. Inc. , respectively, 1 a French-led...
BC Week In Review | Mar 21, 2011
Clinical News

ITX 5061: Phase Ib started

iTherX began an open-label, U.K. Phase Ib trial to evaluate daily 150 mg oral ITX 5061 plus supportive care vs. supportive care alone in about 20 patients for 7 days. iTherX Pharmaceuticals Inc. , San Diego,...
BC Innovations | Nov 18, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Scavenger receptor class B member 1 (SCARB1; SR-B1) Mouse studies suggest that activating SCARB1 could help treat AD. In a mouse model...
BC Innovations | Nov 12, 2009
Distillery Techniques

Technology: Drug delivery

Approach Summary Licensing status Publication and contact information Drug delivery Nanocarriers for targeted therapeutic delivery to cancer cells In vitro and mouse studies suggest that peptide-phospholipid nanocarriers could help deliver cancer compounds to tumor cells....
Items per page:
1 - 10 of 13